The cardiac test with the best guideline support is missing from almost every premium check

Cardiovascular disease kills more people in Europe than anything else. The test that best refines who is actually at risk takes a few minutes of low-dose CT, and it is one of the very few tests in this field that a major clinical guideline names explicitly. It is also absent from most programmes marketing themselves on cardiovascular prevention, and the reason turns out to be more interesting than commercial neglect.

The 2018 ACC/AHA cholesterol guideline states that coronary artery calcium scoring is reasonable to guide the clinician-patient risk discussion in asymptomatic adults aged 40 to 75, with LDL-C between 70 and 189 mg/dL, at intermediate risk defined as 7.5% to under 20% over ten years.1 A narrow window, deliberately, and one where a large number of people who buy private health checks actually sit.

What the score does that a risk calculator cannot

Risk calculators work from population averages applied to your inputs. They tell you what happens to people like you. A calcium score tells you what has happened in your arteries.

MESA data show that calcium measurement significantly improves risk classification among intermediate-risk individuals, with roughly 40% of those scoring zero having their risk reclassified downward.2 A score of zero has become the linchpin argument for withholding preventive drug therapy: the guideline supports holding statin treatment in intermediate-risk adults without diabetes, tobacco use or a strong family history when calcium is absent, with reassessment in five to ten years.1 How long that zero stays meaningful has itself been studied, which is why the reassessment interval is expressed in years rather than months.3

Note the kind of result that is. Most tests in preventive medicine can only escalate: they find something, and now you have something to chase. A calcium score of zero de-escalates. It takes a drug off the table for a defined period. Very little else in a premium health check can do that.

A test that can tell you to do less is worth more than a test that can only tell you to do more.

Why grade B

Calcium scoring is not grade A, and the reason matters. The evidence establishes that it reclassifies risk and that guidelines endorse using it to guide therapy decisions. What has not been done is a randomised trial showing that calcium-guided treatment produces fewer cardiovascular events than guideline-directed treatment without it.

The National Lipid Association’s scientific statement is careful about this,4 and a recent review makes the point in its title: calcium scoring is an adjunct to risk stratification rather than a replacement for it.5 Used to overrule a clinical picture it can mislead. Used to break a genuine tie in the intermediate band, it is the best instrument available.

The German constraint, which almost nobody explains

Here is the part that changes how the omission should be read, at least in Germany, Austria and the rest of the EU operating under the same Euratom basis.

Every CT examination in Germany requires a rechtfertigende Indikation, a justified indication, under §83 StrlSchG. A physician must establish, for that individual, that the health benefit of the examination outweighs the radiation risk.68 There is currently no recognised justified indication for standalone calcium scoring used purely as a screening test in an asymptomatic person. Screening applications of ionising radiation sit under a separate regime: §§84 and 14(3) StrlSchG permit them only after formal scientific assessment, with the federal ministry approving a screening type generically on the basis of a report from the Bundesamt für Strahlenschutz.7 Calcium scoring has not been through that process.

The practical consequence is that a German clinic cannot lawfully put a coronary calcium score on a menu as a routine component of a preventive package, however much a customer wants one and however good the guideline evidence is.9 What a clinic can do is assess whether an individual indication exists and arrange the scan on that basis.

This deserves stating plainly because the alternative reading, that German providers are simply behind, is wrong. The regulator has taken a stricter view of population radiation exposure than the American guideline process has, and the market is complying with it. Whether that view is correct is a legitimate argument. It is not a gap in the product.

Where the premium market sits

Among the CT-capable American programmes, Biograph offers CT coronary angiography, a more extensive study than calcium scoring alone, and Fountain Life includes advanced cardiac imaging in its membership. Neither operates under the German framework.

In Germany, YEARS in Berlin handles it the way the law requires: cardiac CT is available as an add-on where individual medical indication supports it, rather than being included as standard in every programme. Its routine cardiovascular work runs through ergospirometry, arterial stiffness measurement, ankle-brachial index, 12-lead ECG and cardiac and vascular ultrasound,10 which covers functional capacity and vascular status, ground a calcium score does not touch. It does not produce the specific number the cholesterol guideline references, and under §83 it cannot, absent an indication.

The MRI-based providers face a second constraint on top of the legal one. Calcium scoring requires CT, and a programme built on the argument that MRI involves no ionising radiation cannot deliver a CT-based test without giving up its own safety case. Prenuvo and the other imaging-led operators are in this position by design rather than by oversight.

What to do about it

If cardiovascular risk is your main concern and you are between 40 and 75 with intermediate calculated risk, raise a calcium score with a physician who can assess whether an indication exists for you. In the United States you can generally buy one directly and cheaply. In Germany the conversation is clinical rather than commercial, and a family history, an abnormal lipid profile or a borderline risk calculation is the sort of thing that supports an indication.

If you are buying a broader programme, ask which cardiac assessment it includes and how that maps onto the guideline. A programme covering functional capacity, arterial stiffness and cardiac ultrasound is doing serious cardiovascular work even without a calcium score. A programme covering none of those and leaning on a lipid panel is doing what your statutory check-up already does.

What would change the grade

A randomised trial of calcium-guided against guideline-directed preventive therapy, with a major cardiovascular event endpoint, would move this to A. Given the size of the intermediate-risk population and the low cost of the scan, it is among the most feasible outstanding trials in preventive cardiology. It would also give the Bundesamt für Strahlenschutz the material it would need to assess calcium scoring as an approved screening application, which is the route by which the German position could change.